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ABSTRACT  
We assessed here functional connectivity changes in the locus coeruleus (LC) and ventral tegmental 
area (VTA) of patients with Alzheimer’s disease (AD). We recruited 169 patients with either AD or 
amnestic mild cognitive impairment (a-MCI) due to AD and 37 elderly controls, who underwent 
cognitive and neuropsychiatric assessments and resting-state functional MRI at 3T. Connectivity 
was assessed between LC and VTA and the rest of the brain. In a-MCI patients, VTA disconnection 
was predominant with parietal regions, while in AD patients it involved the posterior nodes of the 
default-mode network. We also looked at the association between neuropsychiatric symptoms 
(assessed by the neuropsychiatric inventory) and VTA connectivity. Symptoms such as Agitation, 
Irritability and Disinhibition were associated with VTA connectivity with the parahippocampal 
gyrus and cerebellar vermis, while sleep and eating disorders were associated with VTA 
connectivity to the striatum and the insular cortex. This suggests a contribution of VTA 
degeneration to AD pathophysiology and to the occurrence of neuropsychiatric symptoms. We did 
not find evidence of LC disconnection, but this could explained by the size of this nucleus, which 
makes it difficult to isolate. These results are consistent with animal findings and have potential 
implications for AD prognosis and therapies.  
 
Keywords: Alzheimer’s Disease, VTA, LC, brain disconnection, neuropsychiatric symptoms. 
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1.Introduction 
Alzheimer’s disease (AD) is clinically characterized by neuropsychiatric symptoms in addition to a 
progressive cognitive decline (Alves et al., 2017). The relevance of neuropsychiatric symptoms has 
become increasingly evident as demonstrated by their early occurrence in cognitively intact 
individuals who subsequently develop dementia (Masters et al., 2015). The cholinergic hypothesis 
(Bartus et al., 1982) of AD has been extensively investigated, showing that cholinergic dysfunctions 
in the basal forebrain account for memory deficits in typical AD (Theofilas et al., 2015). It has been 
proposed that AD symptoms may also result from structural and functional abnormalities of the 
dopaminergic (Theofilas et al., 2015) and noradrenergic (Borodovitsyna et al., 2017) systems. The 
noradrenergic (Borodovitsyna et al., 2017) or dopaminergic stimulation (Theofilas et al., 2015) 
leads to a significant improvement of cognitive functions, while their simultaneous stimulation 
reduces both beta-amyloid load and tau pathology (Theofilas et al., 2015). Among the 
dopaminergic-rich nuclei, the ventral tegmental area (VTA) is known to be part of the reward 
system (Nobili et al., 2017; Kreds et al., 2011), and dopaminergic VTA neurons are critically 
implicated in the regulation of several functions, ranging from memory and motivational processes 
(Nobili et al., 2017; Kreds et al., 2011) to sleep-wake behaviours (Eban-Rothschild et al., 2016). 
Consistently, dopaminergic dysfunctions have been implicated in the occurrence of various 
neuropsychiatric symptoms, including mood disorders (Schaeffer & Berg et al., 2017; Ashok & 
Marques, 2017), apathy (Chong & Husaim, 2016), sleep (Kim et al., 2017) and eating disorders 
(Kessler et al., 2016). Most noradrenergic neurons originate from the locus coeruleus (LC), whose 
projections reach the entire cerebral cortex, the thalamic nuclei and the hippocampus (Robertson et 
al., 2013). LC undergoes significant functional and structural modifications in AD (Theofilas et al., 
2015) as confirmed by post-mortem observations (Storga et al., 1996; Francis et al., 1985) and 
supported by neurophysiological studies (Benussi et al., 2017; Gonsalvez et al., 2017). In post-
mortem studies, LC has been shown containing hyperphosphorylated tau (tauHYP), the major 
component of neurofibrillary tangles (NFT), not only in AD patients but also in non-demented 
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individuals decades before the typical age of clinical onset of AD (Braak &amp; Del Tredici, 
2011a; Braak &amp; Del Tredici, 2011b; Pamphlett &amp; Kum Jew, 2015).  According to this 
model, tauHYP that forms early on in life in LC neurons would spread via cell-to cell transfer to 
other neurons to produce NFT (Braak & Del Tredici, 2011a). Damage to the LC with consequent 
decrease in noradrenaline would also promote the formation of Aβ plaques (Heneka et al., 2006; 
Pamphlett & Kum Jew, 2015).  
Taken together these data suggest that a loss of monoaminergic neurons might contribute to 
AD pathophysiology, and might explain some of its clinical manifestation, particularly the 
neuropsychiatric symptoms (Kohler et al., 2016).  
A recent study (Nobili et al., 2017), performed in a transgenic model of AD showed that the 
progressive degeneration of dopaminergic neurons from VTA results in lower dopamine outflow in 
the hippocampus and nucleus accumbens, which correlates with deficits in memory and reward 
processing. Importantly, this dopaminergic loss precedes beta-amyloid plaque deposition, thus 
representing one of the earliest pathological changes in AD. More recently evidence of VTA 
degeneration in association with memory deficits has been provided in patients with AD and MCI 
(De Marco & Venneri., 2018). Interestingly, a recent resting-state functional MRI (fMRI) study 
demonstrated in healthy individuals that VTA and the substantia nigra pars compacta are 
functionally connected to the default mode network (Bär et al., 2016), which is known being 
selectively disrupted in AD since early clinical stages (Gili et al., 2011). Neuropsychiatric 
symptoms are also part of the clinical picture of AD since the early disease stages (Serra et al., 
2010), and dopaminergic dysfunction is likely to play a pathophysiological relevant role for their 
manifestation.  
We hypothesise that, if a loss of dopaminergic neurons occurs in patients with AD from an 
early stage, possibly pre-clinical; and a similar pattern of degeneration occurs to noradrenergic 
neurons originating from the LC, this neuronal loss should result in lower functional connectivity 
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(FC) between the VTA and/or the LC and the rest of the brain. In addition, these changes likely 
account for the occurrence and severity of cognitive and behavioural symptoms. 
While we are unable to address directly the first two hypotheses, we focused on the 
remaining two. To interrogate these hypotheses we recruited a large sample of patients with either 
AD or amnestic mild cognitive impairment (a-MCI) due to AD, and we used resting-state functional 
MRI (fMRI) as a surrogate measure of neuronal degeneration. fMRI assesses the connectivity 
between brain areas by measuring the correlation between spontaneous fluctuations in neuronal 
activity occurring at remote locations (Biswal et al., 1995; Fox et al, 2005). A loss of neurons 
within a specific nucleus, such as LC or VTA, is expected to result in altered connectivity with its 
projection areas. It was previously shown that resting-state fMRI may be used to measure the 
connectivity of small subcortical structures such as the brainstem nuclei (Bianciardi et al., 2017), 
comparable in size to VTA and LC.  
 
 
2.Methods 
2.1 Participants 
A cohort of 169 participants, 84 of them with a diagnosis of probable AD (McKhann et al., 2011) or 
Alzheimer’s clinical syndrome (Jack et al., 2018), 48 with a diagnosis of a-MCI (Albert et al., 
2011), and 37 healthy elderly (HS) subjects were enrolled for this study. The diagnosis of probable 
AD was done according to the clinical criteria of the National Institute of Neurological and 
Communicative Disorders and Stroke-Alzheimer’s Disease and Related Disorders Association 
(NINCDS-ADRDA) (McKhann et al., 2011) and fit with the criteria for Alzheimer’s clinical 
syndrome reported more recently by Jack et al., (2018). The diagnosis of a-MCI was performed 
according to current available criteria (Albert et al., 2011). Patients with a-MCI could be either 
single- (n=24) or multiple (n=24) domains, and had not to respond to the diagnostic criteria for 
major cognitive disorder (APA, 2013), showing a clinical dementia rating (CDR) (Hughes et al., 
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1982) score not exceeding 0.5. Cognitive profile characterized by episodic memory impairment at 
onset, episodic memory deficit documented at formal testing and medial temporal lobe atrophy (see 
below) confirmed that all individuals had a profile supporting Alzheimer’s clinical syndrome at 
different stages.  
Cognitively normal subjects showing the presence of significant medial temporal lobe atrophy were 
excluded. All recruited subjects with a Hachinski score (Hachinski et al., 1975) higher than 4 were 
excluded. Major systemic, psychiatric, and other neurological illnesses (with a special attention to 
Parkinson disease and parkinsonism) were also carefully investigated and excluded in all 
participants. Finally, subjects had to be right-handed, as assessed by the Edinburgh Handedness 
Inventory (Büsch et al., 2010). The main demographic and clinical characteristics of the participants 
are summarized in Table 1, together with data about their medication. 
This study was approved by the Ethical Committee of Santa Lucia Foundation, and written 
informed consent was obtained from all participants before study initiation. All procedures 
performed in this study were in accordance with the 1964 Helsinki declaration and its later 
amendments or comparable ethical standards.  
 
2.2 Neuropsychological and behavioural assessment  
All participants underwent an extensive neuropsychological battery covering all cognitive domains, 
which included: a) verbal episodic long-term memory:15-Word List (Immediate, 15-min Delayed 
recall and recognition) (Carlesimo et al., 1996); Short Story Test (Immediate and 20-min Delayed 
recall) (Carlesimo et al., 2002); b) visuo-spatial long-term memory: Complex Rey’s Figure 
(Immediate and 20-min Delayed recall) (Carlesimo et al., 2002); c) short-term and working 
memory: Digit span (forward and backward) and the Corsi Block Tapping task (forward and 
backward) (Monaco et al., 2013); d) executive functions: Phonological Word Fluency (Carlesimo et 
al., 1996) and Modified Card Sorting Test (Nocentini et al., 2002); e) language: Naming objects 
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subtest of the BADA (‘‘Batteria per l’Analisi dei Deficit Afasici’’, Italian for ‘‘Battery for the 
analysis of aphasic deficits’’) (Miceli et al., 1991); f) Reasoning: Raven’s Coloured Progressive 
Matrices (Carlesimo et al., 1996); g) constructional praxis: copy of simple drawings with and 
without landmarks (Carlesimo et al., 1996)  and copy of Complex Rey’s Figure (Carlesimo et al., 
2002); h) general cognitive efficiency: Mini Mental State Examination (MMSE) (Folstein et al., 
1975; Measso et al., 1993). For the purposes of the current study neuropsychological scores were 
adjusted for age and education, as reported in the corresponding references. Nineteen one-way 
ANOVAs were used to assess between group differences in neuropsychological performances. To 
avoid the type-I error Bonferroni’s correction was applied (p value threshold α= 0.05/19= 0.003). 
For the neuropsychiatric assessment, AD and a-MCI patients’ caregivers were required to complete 
the Neuropsychiatric Inventory (NPI-12) (Cummings, 1997). This scale assesses the presence and 
severity of delusions, hallucinations, agitation/aggression, dysphoria/depression, anxiety, 
euphoria/elation, apathy, disinhibition, irritability/lability, aberrant motor behaviour, sleep and 
eating disturbances. Each item’s score ranges from 0 to 12, and reflects both, ratings of severity and 
frequency of each behavioural symptom, with 0 corresponding to the absence of behavioural 
symptom and 12 corresponding to its maximum frequency and severity.  
A factor analysis was used to extract in AD and a-MCI patients main factors from NPI-12. Factor 
analysis describes variability among observed correlated variables in terms of a potentially lower 
number of unobserved variables called factors. In the present case we hypothesized that the factors 
represented the common variance in the 12 subscales of NPI-12. Each NPI-12’s score (frequency by 
severity) entered as variables of interest in factor analyses. Factor analyses were performed using 
the Maximum Likelihood estimation method (with eigenvalues >1 for the factors’ extraction, and 
VARIMAX method for factors’ rotation). Factors extracted from NPI-12 were then used in the MRI 
data analyses.  
A trained psychologist screened healthy elderly subjects to exclude any psychopathological 
symptom on the basis of dedicated clinical interviews.  
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Statistics to assess differences in symptoms’ occurrence across patients’ subgroups was performed 
using a series of Chi-square tests. 
2.3 MRI acquisition 
All imaging was obtained, in a single session, using a head only 3.0T MRI scanner (Siemens 
Magnetom Allegra, Siemens Medical Solutions, Erlangen, Germany). The MRI acquisition protocol 
included: (a) a dual-echo turbo spin echo (TSE) (repetition time (TR)=6190 ms, echo times 
(TE)=12/109 ms, echo train length (ETL)=5; matrix=256×192; FOV=230×172.5 mm2; 48 
contiguous 3 mm thick slices); (b) a fast fluid attenuated inversion recovery (FLAIR) (TR=8170 
ms, TE=96 ms, inversion time (TI)=2100 ms; ETL=13; with same FOV, matrix and number of 
slices as TSE) (c) 3D Modified Driven Equilibrium Fourier Transform (MDEFT) scan (TR=1338 
ms, TE=2.4 ms, Matrix=256x224, n. slices=176, thickness=1 mm); (d) a T2*-weighted echo-planar 
imaging (EPI) sensitized to BOLD contrast (TR=2080 ms, TE=30 ms, 32 axial slices parallel to 
AC-PC line, matrix=64×64, pixel size=3×3 mm2, slice thickness=2.5 mm, flip angle=70°) for 
resting-state fMRI (total number of volumes=220). During this acquisition, subjects were instructed 
to keep their eyes closed, not to think of anything in particular, and not to fall asleep. 
2.3.1 Medial temporal lobe atrophy 
The Medial Temporal lobe Atrophy scale (MTA) (Scheltens et al., 1995) was employed to assess on 
volumetric images (MDEFT) the presence and severity of atrophy in each subject. This scale 
provides a rating score from 0 to 4, with scores>1.5 (Pereira et al., 2004) indicating significant 
atrophy. For each subject, we averaged the scores obtained in the right and left hemispheres to 
obtain a single measure of medial-temporal lobe atrophy. One-way ANOVA was employed to 
control for between group differences. 
2.3.2 Image Analysis of resting-state fMRI data 
Images were pre-processed for resting-state fMRI using Statistical Parametric Mapping version 8 
(SPM8, http://www.fil.ion.ucl.ac.uk/spm/), and in-house Matlab scripts as previously described 
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(Bozzali et al., 2015). First, every participant’s MDEFT was segmented in SPM8 in order to obtain 
participany-specific white matter and CSF masks, as well as to estimate the total GM volume.  
As both VTA and LC are very small, we followed a pipeline similar to that described by Bär et al 
(Bär et al., 2016). For each participant, the first four volumes of the fMRI series were discarded to 
allow for T1 equilibration effects. The pre-processing steps included correction for head motion, 
compensation for slice-dependent time shifts, and normalization to the EPI template in MNI 
coordinates provided with SPM8. For each data set, motion correction was checked to ensure that 
the maximum absolute shift did not exceed 1.5 mm and the maximum absolute rotation did not 
exceed 1°. Datasets not fulfilling these criteria were removed. In addition, in order to minimise the 
risk that our results were affected by differing degree of motion for the 3 participants’ groups, we 
computed the global correlation (GCORR, Saad et al. 2013), the average mean displacement (root 
mean square or RMS of the 6 realignment parameters) and the average frame-wise displacement 
(FD, Power et al, 2012) and compared them between AD and HS, and between MCI and HS, 
respectively, using independent sample T-tests. The signal in every voxel was regressed against the 
average white matter and CSF signals, as well as against the 6 realignment parameters. Then, all 
images were filtered by a phase-insensitive band-pass filter (pass band 0.01–0.08 Hz) to reduce the 
effect of low-frequency drift and high-frequency physiological noise. We refer to these datasets as 
unsmoothed corrected data. These data were then smoothed via filtering with a 3D Gaussian kernel 
with 10 mm3 full width at half maximum. 
2.3.3 Seed-Based Analyses 
Standard space seed masks of the left and right VTA and LC were produced using the Harvard 
Ascending Arousal Network Atlas in MGH152_1mm Space (https://www.martinos.org/) (Edlow et 
al., 2012)  (Fig. 1).  
Insert Fig.1 around here 
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The mean time course within each seed region was extracted (from the unsmoothed corrected data) 
for every participant (averaged for left and right sides). This was done to minimize the partial 
volume contamination from neighboring nuclei.  The smoothed data were then regressed voxel-wise 
against these time courses in a first-level SPM8 analysis (Olivito et al., 2017). The resulting beta 
images were taken to the second level for a random-effect group analysis. At second level, 2 full 
factorial models (with a 3-level factor modelling the group) were used to assess between-group 
differences in VTA and LC functional connectivity (FC), separately. 
Next, we assessed the potential associations between the NPI-12’s factors and FC changes in  
a-MCI and AD patients using multiple regression models. In order to do that, we selected some a-
priori spherical (radius = 6mm) regions of interest (ROIs), centred in the peak coordinates of the 
clusters that showed differences in connectivity between patients and controls. The mean 
connectivity in these areas was extracted and correlated with the 5 factors using Pearson’s 
correlation coefficient. In addition, we performed a more exploratory analysis, looking at the whole 
brain is SPM. Five separate whole-brain analyses were performed for each factor. In all analyses, 
whole-brain GM volumes and years of formal education were entered as covariates of no interest. 
Statistical significance was always set at p < 0.05 FWE-corrected at cluster level. 
 
3. Results 
3.1 Demographic and clinical characteristics 
There were no significant differences between groups in age, and gender distribution (Table 1). 
There were significant differences across groups in years of formal education.  
 
3.2 Neuropsychological assessment 
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As expected, AD patients showed significantly worse performances than a-MCI patients and HS in 
each administered test. A-MCI patients showed worse performances than HS in tests assessing 
episodic memory and executive functions. Details of the neuropsychological assessment are 
summarized (Table 2). 
3.3 Neuropsychiatric assessment 
Fig. 2 shows, for the Neuropsychiatric Inventory-12 (NPI-12) subscale, the percentage of patients 
who reported a score higher than 0.  
Insert Fig.2 around here 
As expected, patients with AD showed a significantly higher occurrence than patients with a-MCI 
in the following NPI-12 subscales: delusions (15 out of 84 AD patients [17.8%], vs. 1 out of 48 a-
MCI patients [2.1%], Chi-square=7.13, df=1, p=0.007); agitation (34 out of 84 AD patients 
[40.5%], vs. 11 out of 48 a-MCI patients [22.9%], Chi-square=4.19, df=1, p=0.04); euphoria (10 out 
of 84 AD patients [11.9%], vs. 1 out of 48 a-MCI patients [2.1%], Chi-square=3.86, df=1, p=0.04); 
disinhibition (19 out of 84 AD patients [21.4%], vs. 4 out of 48 a-MCI  patients [4.8%], Chi-
square=4.33, df=1, p=0.03); motor aberrant behaviour (19 out of 84 AD patients [21.4%], vs. 1 out 
of 48 a-MCI patients [2.1%], Chi-square=10.0, df=1, p=0.001).  When adjusting for multiple 
comparisons using Bonferroni correction (threshold for significance p = 0.05/12 = 0.004), only 
motor aberrant behaviour remains significantly different.  Interestingly, the two groups of patients 
showed no statistical differences in the high occurrence of the following NPI-12 subscales: 
depression (43 out of 84 AD patients [51.1%], vs. 21 out of 48 a-MCI patients [43.7%], Chi-
square=0.68, df=1, p=0.41); apathy (49 out of 84 AD patients [58.3%], vs. 21 out of 48 a-MCI 
patients [43.7%], Chi-square=2.61, df=1, p=0.11); anxiety (39 out of 84 AD patients [46.4%], vs. 
21 out of 48 a-MCI patients [43.7%], Chi-square=0.09, df=1, p=0.77); irritability (37 out of 84 AD 
patients [44.0%], vs. 18 out of 48 a-MCI patients [37.5%], Chi-square=0.54, df=1, p=0.46); sleep 
disorders (23 out of 84 AD patients [27.3%], vs. 12 out of 48 a-MCI patients [25.0%], Chi-
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square=0.09, df=1, p=0.76); eating disorders: (23 out of 84 AD patients [27.3%], vs. 8 out of 48 a-
MCI patients [16.7%], Chi-square=1.95, df=1, p=0.16). Finally, both patient groups showed low 
occurrence in hallucinations (4 out of 84 AD patients [4.8%], vs. 1 out of 48 a-MCI patients [2.1%], 
Chi-square=0.6, df=1, p=0.44).  
Overall, apathy, depression and anxiety were the most frequent behavioural symptoms observed in 
our patient cohort, with no significant differences between AD and a-MCI. 
From the initial 12 NPI subscales entered in the factor analysis (see Table 3) five factors were 
extracted (54.9% of variance). The NPI-12 subscales reporting a saturation threshold > 0.35 
(Overall & Klett, 1972) were included in a factor as follow: Agitation, Irritability and Disinhibition 
in Factor 1; Hallucination, and Delusions in Factor 2; Depression and Apathy in Factor 3; Euphoria 
and Aberrant Motor Behaviour in Factor 4; Eating and sleep disorders in Factor 5.  
Based on this classification, 44 patients presented with the symptoms grouped in Factor 1(31 AD 
and 13 a-MCI-; Chi-square=1.33, df=1, p=0.249), 22 patients with those in Factor 2(15 AD and 7 a-
MCI; Chi-square=0.24, df=1, p=0.627), 48 patients with those in Factor 3(31 AD and 17 a-MCI; 
Chi-square=0.03, df=1, p=0.864), 18 patients with those in Factor 4 (17 AD and 1 a-MCI; Chi-
square=8.55, df=1, p=0.003), and 34 patients with those in Factor 5(24 AD and 10 a-MCI; Chi-
square=0.96, df=1, p=0.328). 
3.4 Medial temporal lobe atrophy 
None of the HS showed evidence of clinically relevant hippocampal atrophy (MTA<1). All patients 
(a-MCI and AD) reported MTA scores significantly higher than those reported HS (Table 1).  
3.5 Functional brain connectivity 
3.5.1 Changes in functional connectivity within the brainstem monoaminergic nuclei across 
Alzheimer’s disease stages. 
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Four participants with AD, one with a-MCI and one HS were removed from the analysis because of 
excessive movement. After removing them, there were no significant differences between groups in 
any of the following: GCORR (Ad vs HS, p=0.75; MCI vs HS, p=0.17); mean motion parameters 
RMS (AD vs HS, p=0.24; MCI vs HS, p=0.47); mean FD (AD vs HS, p=0.51; MCI vs HS, p= 0.47, 
and 0.51). 
In HS, the VTA was functionally connected to the main nodes of the DMN (See Fig 3A), while LC 
was connected to some of the nodes of the salience network (the insular cortices and with basal 
ganglia) as well as with the orbito-frontal and the parahippocampal cortices (Fig 3B). Similar 
patterns were observed also in a-MCI and AD, although qualitatively the connectivity appears 
reduced. 
Insert Fig.3 around here 
 
Quantitatively, compared to healthy elderly subjects, patients with a-MCI showed lower FC in VTA 
and in the right parietal lobule (BA7). AD patients showed lower FC than HS between VTA and the 
posterior cingulate cortex (PCC), precuneus, and parietal lobule bilaterally (BA7). No changes were 
found in the opposite direction. These results are summarised in Fig. 4. Conversely, when looking 
at LC connectivity there were no between-group changes that reached statistical significance. As 
discussed below, this is likely due to the low resolution power of our MRI data to LC whose size is 
relatively small. 
Insert Fig.4 around here 
 
3.5.2 Associations between monoaminergic brainstem nuclei connectivity and prevalence of 
behavioural symptoms 
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Based on the results of the group comparison, ROI-based associations were investigated in three 
ROIs: the posterior cingulate cortex (MNI coordinates [0 -32 34]), the right angular gyrus (MNI 
coordinates [38 -68 48], and the left angular gyrus (MNI coordinates [-36 -74 44]). No significant 
association was found. 
For the whole brain analysis, significant associations were found between VTA connectivity and 
behavioural symptoms expressed by Factor 1 (i.e., agitation, irritability and disinhibition) and 
Factor 5 (i.e., sleep and eating disorders). Factor 1 was positively correlated with connectivity 
between VTA and the right hippocampus, and the cerebellum bilaterally. Factor 5 showed a 
positive correlation with connectivity between VTA and the left putamen and inferior frontal gyrus 
(see Figure 5, green). The same factor was also negatively correlated with functional connectivity 
between VTA and the left caudate (see Figure 5, magenta).  
   Insert Fig.5 around here 
 
4.Discussion 
Over the last 10 years it has become increasingly clear that specific brain stem regions play a 
modulatory role in various cognitive and behavioural aspects that accompany aging (Bartus et al., 
1982). Among them, VTA and LC are of particular interest, as they are believed to cooperate in a 
number of physiological functions from cognition to social behaviour (Park et al., 2012). The main 
goal of this study was to assess whether changes in VTA and LC connectivity - used as a proxy of 
neuronal loss - are present in AD and may account for higher level dysfunctions, as strongly 
suggested by animal model evidence (Nobili et al., 2017). VTA degeneration was indeed suggested 
to precede amyloid plaque formation, while a very early involvement of LC (Braak & Del Tredici, 
2011a; Braak & Del Tredici, 2011b; Theofilas et al., 2017) was demonstrated in AD brains as 
associated to accumulation of neurofibrillary tangles (Andrés-Benito et al., 2017). For this reason, 
we included in our study patients at early (a-MCI) and intermediate stages of AD. The clinical, 
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radiological (MTA) and neuropsychological characteristics of our sample suggest a diagnosis of 
Alzheimer’s clinical syndrome (McKhann et al., 2011; Albert et al., 2011; Jack et al., 2018). In line 
with our hypothesis and with previous animal work (Nobili et al., 2017), we found evidence of 
VTA disconnection with the right parietal lobe (BA7) in a-MCI. These results are consistent with 
previous observations that degeneration of dopaminergic neurons in VTA is already present in the 
pre-plaque mouse model of AD stage (Nobili et al., 2017). In the animal model, VTA degeneration 
was found to contribute to the memory deficits and dysfunction of reward processing (Nobili et al., 
2017), which are regarded as motivated behaviours. In AD, the pattern of VTA disconnection 
extended to additional parietal areas, with a substantial involvement of the cingulate cortex and 
precuneus. These findings support the hypothesis of a progressive degeneration on VTA neurons 
with AD progression. Interestingly, this pattern largely overlaps with the major nodes of the so-
called default mode network (DMN) (Gili et al., 2011), including the posterior cingulate cortex and 
precuneus, and the right parietal node. AD patients were characterised by a more extensive 
disconnection in these areas than patients with a-MCI. It was previously argued that disconnection 
in the posterior cingulate cortex is a critical transitional step for the conversion from a-MCI to AD 
(Gili et al., 2011; Bozzali et al., 2012). Additionally, VTA and the substantia nigra pars compacta 
were demonstrated being functionally connected to regions of the default mode network in healthy 
controls (Bär et al., 2016). Our current findings suggest that the often reported disconnection within 
the DMN (Seeley et al., 2006) might not be caused only by loss of neurons from the medial 
temporal lobes, but also associated with VTA dysfunction. In contrast to our working hypothesis 
and previous literature (Braak and Del Tredici, 2011a; Braak and Del Tredici, 2011b; Theofilas et 
al., 2017; Andrés-Benito et al., 2017; Jacobs at al., 2015) we were unable to identify any significant 
changes in functional connectivity between LC and the rest of the brain in both patient groups (at 
the statistical thresholds chosen for this study). Considering the small size of LC we argue that this 
nucleus is below the resolution power of our MRI data, and therefore we are unable to draw 
conclusions about LC connectivity in our patient cohort. Admittedly, Jacobs and co-authors (2015), 
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using resting state fMRI, have previously reported reduced LC connectivity with the 
parahippocampal gyrus in patients with a-MCI that correlated with memory performance (Jacobs at 
al., 2015). There are some technical differences that might at least partially account for the 
inconsistency of our current results. First, Jacobs and co-authors warped the seed-masks into each 
participant's native space, while we extracted the time series from warped data, and then used 
smoothed data (4mm FWHM). Second they used a different method to correct for multiple 
comparisons. We also observed some connectivity changes in the LC of AD patients when using 
less stringent statistical thresholds (data not shown).  
From a clinical point of view, VTA degeneration has been recently associated to memory 
dysfunction in AD and a-MCI patients (De Marco & Venneri,2018). The dopaminergic system is 
known to be remarkably implicated in behavioral and psychological aspects, thus the loss of 
dopaminergic neurons could be particularly relevant for the manifestation of psychiatric symptoms 
in AD. These symptoms are frequently observed in AD, and are known to become increasingly 
worse along with disease progression (Alves et al., 2017; Masters et al., 2015). Behavioural 
symptoms have been previously reported also in a-MCI patients, although they have not been 
univocally associated with neurodegeneration (Gonsalvez et al., 2017; Serra et al., 2010; Makovac 
et al., 2016). In order to establish whether VTA degeneration and disconnection could account for 
behavioural symptoms we investigated the association between VTA FC and NPI-12 factors. We 
could not find clear evidence that the loss of connectivity between VTA and the nodes of the DMN 
impacts on behavioural symptoms. However, in a more exploratory, whole-brain analysis, we found 
significant associations with Factor 5 (including sleep and eating disorders) and with Factor 1 
(including agitation, irritability and disinhibition). Interestingly, Factor 5 showed both increased 
VTA connectivity mainly in the putamen and reduced connectivity in the caudate. The basal ganglia 
play a well-known role in regulating sleep and wakefulness (Rolinski et al., 2016), and sleeping 
disorders are frequently associated with other neurological disease, such as Parkinson’s disease, that 
affect the basal ganglia. Moreover, reduced activity in the caudate has been found also in the in 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
17 
 
subject suffering from insomnia (Stoffers et al., 2014). In addition, we found also increased 
connectivity related to Factor 1 in the hippocampus and in the cerebellum, two brain areas 
innervated by VTA dopaminergic neurons (Ikai et al., 1992).  
The association with the cerebellum is particularly intriguing considered its contribution to the 
cognitive and neuropsychiatric deficits in AD (Jacobs et al., 2018; Vermeiren et al, 2014) and the 
role of dopamine in the cerebellum functions beyond the coordination of voluntary motor activity 
and motor learning. We previously found an association between hippocampal atrophy and positive 
behavioural symptoms in patients with AD (Serra et al., 2010). Unexpectedly the direction of this 
correlation suggests that increased connectivity between these areas and VTA are associated with 
worsening in behavioural symptoms. As we did not find any evidence of increased connectivity 
between the areas of the DMN and VTA, an intriguing interpretation (although very speculative at 
this stage) is that disengagement of the VTA from the DMN might lead to an increased connectivity 
between the same area and the salience network.  
This study also suffers from some limitations. First of all, VTA and LC are very small nuclei, and 
they are difficult to identify on MRI. It is therefore possible that some of our results are affected by 
partial volume with neighbouring structures of the brainstem. Nevertheless, we have tried to 
minimise these effects by extracting the time-series from unsmoothed data. Another potential 
confound comes from respiration and pulsatility artifacts, to which these areas are particularly 
susceptible. Ideally, these can be accounted for when acquiring respiration data concomitant with 
fMRI. Unfortunately we did not have these data. We could have also adopted more sophisticated 
post-processing approaches, such as regressing out GCORR (Saad et al, 2013) or complementing 
whole-brain co-registration with a further, brainstem-weighted registration (Napadao et al, 2006). 
Nevertheless, the comparisons we computed for 3 parameters reflecting global motion (GCORR, 
RMS and FD) suggest that it was comparable among groups. Third, we defined the nuclei using an 
atlas in standard space (due to the aforementioned difficulties in identifying each nucleus on 
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subject-specific MRI). A more accurate location could have been achieved by registering the 
standard ROI to each participant’s scan (Jacobs et al., 2015). Additionally, if the nuclei under 
observation are characterised by macroscopic atrophy, it is possible that this might influence the 
results of our connectivity analysis. However, for the motivations explained above, it is not possible 
to measure the volume of each nucleus independently, and thus adjust for this potential confound. 
Finally, we did not have access to information of amyloid in our cohort, either from CSF analysis or 
PET imaging. This information would increase the diagnostic confidence, particularly in view of 
the most recent criteria, which require amyloid and tau biomarkers for the diagnosis of AD (Jack et 
al., 2018). Unfortunately, these biomarkers were not available in our cohort of patients and this is a 
limitation of the study. It therefore possible that some of the participants might have other forms of 
dementia, such as fronto-temporal lobar degeneration. Nevertheless, this is highly unlikely because 
the whole cohort showed clinical (episodic memory disorder at onset), radiological (hippocampal 
atrophy) and neuropsychological (memory disorders confirmed by formal tests) features suggesting 
the presence of an Alzheimer’s clinical syndrome at different clinical stages (McKhann et al., 2011; 
Albert et al., 2011; Jack et al., 2018).  
In addition, despite the performance of patients with AD at language tests (naming of objects) being 
significantly worse than that of controls and a-MCI participants, on average it was still within the 
range of normality (mean = 24, cutoff=22), thus minimising the likelihood that they had 
frontotemporal degeneration.  Because of the specific focus of this study, it would have been useful 
also to measure dopamine levels to support the MRI findings. 
In summary, the current study has identified a progressive functional disconnection between 
VTA and several brain regions, measurable since the a-MCI stage. These FC changes are likely to 
reflect a progressive dopaminergic dysregulation, and it might account for several behavioural 
symptoms, including circadian disorders and agitation, irritability and disihibition observed in both 
a-MCI and AD patients. Although, the role of dopaminergic system in early AD patients are not 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
19 
 
fully explored, this clinical investigation providing compelling evidence of altered connectivity 
between VTA, and some key brain regions involved in AD pathology.  
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Figure legends 
Fig. 1 Seed areas used to assess connectivity in VTA and LC 
The figure illustrates the anatomical points used as seed to assess connectivity starting from VTA 
(in red) and LC (in blue). For the anatomical definition of VTA and LC the Harvard AAN Atlas has 
been used (https://www.martinos.org/) (Edlow et al., 2012). For the purpose of the illustration the 
VTA and LC are overlaid onto the Ch2bet template using mricron 
(http://people.cas.sc.edu/rorden/mricron/). 
Abbreviations: AAN=Ascending Arousal Network; LC= Locus Coeruleus; VTA= Ventral 
Tegmental Area 
See text for further details  
 
Fig. 2 Neuropsychiatric symptoms in patients with a-MCI and AD 
The figure shows the prevalence of behavioural symptoms in a-MCI (in blue) and AD (in red) 
patients, as assessed by NPI-12. 
* AD vs a-MCI p<0.05; 
Abbreviations: a-MCI= amnestic Mild Cognitive Impairment; AD= Alzheimer’s Disease; NPI-12= 
Neuropsychiatric inventory-12; A. Motor Behv= Aberrant Motor Behaviour 
See text for further details  
 
Fig. 3 Patterns of functional connectivity between VTA and LC and the rest of the brain 
across groups. 
A) VTA connectivity. VTA was connected mainly with the nodes of Default Mode Network, with 
the mediotemporal regions and with basal ganglia (in panel A). This pattern was progressively less 
significant moving from HS to AD. 
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B) LC connectivity. LC was connected mainly with the orbito-frontal, the parahippocampal, the 
insular cortices and with basal ganglia. 
The results are overlaid onto the Ch2bet template using mricron 
(http://people.cas.sc.edu/rorden/mricron/). 
Abbreviations: a-MCI= amnestic Mild Cognitive Impairment; AD= Alzheimer’s Disease; FC= 
Functional connectivity; HS= Healthy Subjects; L= Left. 
See text for further details  
 
Fig.4 Reductions in VTA connectivity between patients and healthy controls.  
Patients with a-MCI compared to HS (in blue) showed reduced FC and the right parietal lobule. AD 
patients compared to HS (in red) showed lower functional connectivity and PCC, and precuneus 
and parietal lobules bilaterally. The overlapping areas are shown in purple. The results are FWE-
corrected at cluster level (p < 0.05) and overlaid onto the Ch2bet template using mricron 
(http://people.cas.sc.edu/rorden/mricron/). 
Abbreviations: a-MCI= amnestic Mild Cognitive Impairment; AD= Alzheimer’s Disease; FC= 
Functional connectivity; FWE= Family Wise Error; HS= Healthy Subjects; PCC= Posterior 
Cingulate Cortex; L= Left.  
See text for further details  
 
Fig. 5. Correlations between neuropsyhciatric factors and VTA connectivity. 
Of the 5 factors explaining the majority of the variance in NPI-12 (see text), we found significant 
associations of VTA connectivity with Factor 1 (Agitation, Irritability and Disinhibition) and with 
Factor 5 (eating and sleep disorders). Direct associations with Factor 1 were found in the right 
hippocampus and the cerebellum bilaterally (top left, in cyan). Both positive (in green) and negative 
(in magenta) associations were found with Factor 5 (bottom), in  left putamen/inferior frontal gyrus 
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and the left caudate, respectively. The results are FWE-corrected at cluster level (p < 0.05) and 
overlaid onto the Ch2bet template using mricron (http://people.cas.sc.edu/rorden/mricron/). 
Abbreviations: FWE= Family Wise Error; L= Left.  
See text for further details  
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Table 1. Principal demographic and clinical characteristics of the participants. 
Mean (SD) AD 
N=84 
a-MCI 
N=48 
HS 
N=37 
Statistics p-value 
Age [years] 73.1 (6.2) 71.8 (7.4) 70.7 (5.3) F2.166=1.99 0.139 
Gender (M/F) 34/50 24/24 16/21 Chi12<1.13 <0.78 
Education [years] 9.3 (4.3)* 9.9 (4.6) § 12.6 (3.5) F2.166=8.01 0.001 
MMSE score 20.4 (4.0)* # 26.1 (1.6) § 28.3 (1.9) F2.166=105.05 0.000 
MTA score 2.8 (0.8) * # 2.2 (0.9) § 0.7 (0.6) F2.166=88.41 0.000 
 
Medication: N (%) 
    
Benzodiazepines 7/84 (8%) 6/48 (12.5%) - Chi12=0.6 0.43 
Antidepressants 21/84 (25%) 14/48 (29.1%) - Chi12=0.2 0.63 
Neuroleptics 6/84 (7%) - - - - 
AChEIs 35/84 (41.6%) - - - - 
 
Tukey’s post-hoc comparisons: * AD vs. HS p-value<0.05; #AD vs. a-MCI p-value<0.05; §a-MCI vs. HS 
p-value<0.05. 
Abbreviations: AChEIs=Acetylcholinesterase inhibitors; AD=Alzheimer’s Disease; a-MCI=amnestic 
Mild Cognitive Impairment; HS=healthy subjects; MMSE=Mini Mental State Examination; MTA=medial 
temporal atrophy scale.  
See text for further details. 
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Table 2. Performance obtained by participants on neuropsychological testing. 
 
Neuropsychological test 
 
     
AD a-MCI HS F p-value 
 
Verbal episodic memory 
15-Word List: 
     
     
Immediate recall (cut-off > 28.5) 24.8 (8.8)*# 30.9 (5.6) § 44.6 (8.8) F2.166=77.15 0.000 
Delayed recall (cut-off > 4.6) 2.8 (2.4) *# 4.4 (2.4) § 9.4 (2.3) F2.166=94.78 0.000 
Recognition hit rates 8.4 (3.9) *# 10.7 (2.9) § 13.3 (1.6) F2.166=25.05 0.000 
Recognition false 6.3 (6.7) *# 5.8 (5.2) § 1.7 (1.7) F2.166=7.54 0.001 
Short Story:      
Immediate recall (cut-off > 3.1) 1.0 (1.7) *# 3.3 (2.4) § 5.3 (1.5) F2.166=55.70 0.000 
Immediate recall (cut-off > 2.8) 1.1 (1.9) *# 3.7 (2.4) § 5.5 (1.5) F2.166=50.41 0.000 
Visuo-spatial episodic memory 
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Rey’s Complex Figure      
Immediate recall (cut-off > 6.4) 7.2 (5.2) *# 10.9 (6.1) § 16.1 (6.6) F2.166=24.66 0.000 
Delayed recall (cut-off > 6.3) 6.0 (5.3) *# 9.9 (6.8) § 16.1 (5.6) F2.166=31.41 0.000 
Verbal short-term memory      
Digit Span forward (cut-off > 3.7) 4.8 (1.1) * 5.2 (0.9) 5.7 (1.1) F2.166=10.19 0.001 
Digit Span backward 2.8 (1.6) *# 3.6 (1.3) 4.3 (0.7) F2.166=15.53 0.000 
Visuo-spatial short-term memory      
Corsi Span forward (cut-off > 3.5) 3.8 (1.5) *# 4.5 (0.6) 5.1 (0.8) F2.166=16.03 0.000 
Corsi Span backward 2.8 (1.9) *# 3.7 (1.2) 4.6 (0.9) F2.166=13.61 0.000 
Executive functions      
Phonological verbal fluency 
 (cut-off > 17.3) 
23.0 (10.5) *# 29.6 (6.7) § 36.3 (10.2) F2.166=25.56 0.000 
Modified Card Sorting Test  
Criteria achieved (cut-off > 17.3) 
2.3 (1.7) *# 3.8 (2.0) § 5.7 (0.6) F2.166=43.22 0.000 
Reasoning      
Raven’s Progressive Matrices  
(cut-off > 18.9) 
22.6 (8.0) *# 27.0 (4.8) § 31.6 (3.7) F2.166=25.26 0.000 
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Language      
Naming of objects  (cut-off > 22) 24.4 (7.9) *# 28.2 (1.9) 28.5 (2.1) F2.166=8.94 0.001 
Constructional praxis      
Copy of drawings (cut-off > 7.1) 7.6 (3.5) *# 9.5 (1.8) 10.8 (1.1) F2.166=18.15 0.000 
Copy of drawings with landmarks (cut-off > 61.8) 56.8 (19.1) *# 66.5 (3.8) 69.3 (0.8) F2.166=11.55 0.000 
Rey’s Complex Figure-Copy (cut-off >23.7) 22.9 (11.2) *# 29.4 (7.1) 32.3 (3.6) F2.166=14.22 0.000 
 
Tukey’s post-hoc comparisons: * AD vs. HS p-value<0.05; #AD vs. a-MCI p-value<0.05; §a-MCI vs. HS p-value<0.05. 
See text for further details 
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Table 3. Results of factor analysis in patients’ group 
Total variance explained 
Factor  Initial Eigenvalues Extraction Sum of Squares 
Loadings# 
Rotate Extraction Sum of Squares Loadings* 
 Total % of 
Variance 
% Cumulative Total % of 
Variance 
% 
Cumulative 
Total % of 
Variance 
% Cumulative 
1 3.36 28.02 28.02 2.22 18.48 18.48 1.67 13.91 13.91 
2 1.60 13.27 41.30 0.80 6.70 25.17 1.43 11.95 25.85 
3 1.24 10.30 51.59 1.73 14.42 39.60 1.35 11.27 36.13 
4 1.19 9.89 61.48 1.18 9.84 49.43 1.19 9.96 47.09 
5 1.02 8.50 69.98 0.67 5.56 54.99 0.95 7.90 54.99 
6 0.88 7.36 77.34       
7 0.69 5.78 83.12       
8 0.55 4.63 87.74       
9 0.49 4.10 91.84       
10 0.38 3.13 94.97       
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11 0.37 3.07 98.04       
12 0.23 1.95 100       
Communalities and rotated factor matrix  
 Communalities# Rotated Factor Matrix* 
 Initial Extraction Factor 1 Factor 2 Factor 3 Factor 4 Factor 5 
Delusions 0.29 0.25 0.17 0.37 0.25 0.13 0.03     
Hallucination 0.48 0.99 -0.01 0.97 0.10 0.20 0.09     
Agitation 0.43 0.51 0.67 0.02 0.19 0.16 -0.03     
Depression 0.35 0.84 0.03 0.07 0.91 0.04 -0.04     
Anxiety 0.17 0.10 0.13 0.06 0.24 -0.04 0.14     
Euphoria 0.25 0.18 -0.03 0.18 -0.01 0.35 0.14     
Apathy 0.36 0.39 0.27 0.09 0.52 0.05 0.17     
Disinhibition 0.56 0.60 0.54 0.47 -0.05 0.19 0.24     
Irritability 0.53 0.72 0.80 0.05 0.23 -0.05 0.14     
Ab. Mot Beh. 0.34 0.99 0.23 0.12 0.05 0.96 0.07     
Sleep 0.21 0.39 -0.03 -0.01 0.11 0.13 0.60     
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Eating dis. 0.41 0.62 0.32 0.26 0.07 0.09 0.65     
# Extraction method: Maximum Likelihood; *Rotation method: Varimax with Kaiser Normalization; in bold the variables included in 
each factor according the saturation threshold> 0.35  (Overall & Klett, 1972). 
Abbreviation:  Ab. Mot Beh= Aberrant Motor Behaviour.
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Highlights 
Dopaminergic and adrenergic loss are key feature of AD in animal models 
VTA is connected with the default mode network, while LC with the salience network 
VTA disconnection characterizes AD at different stages.  
VTA disconnection accounts for some neuropsychiatric symptoms in AD 
This has potential implications for AD prognosis and therapies. 
 
